Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dextromethorphan bill

This article was originally published in The Tan Sheet

Executive Summary

Sale of unfinished dextromethorphan would be restricted to entities registered with FDA under the "Dextromethorphan Distribution Act of 2006" (HR 5280) introduced May 3 by Reps. Fred Upton (R-Mich.) and Rick Larsen (D-Wash.). The cough suppressant bulk ingredient has been abused by "individuals, including teenagers," the bill notes. The HHS Secretary will be required to issue a final rule restricting distribution of unfinished dex within 180 days of enactment if the bill passes. The Consumer Healthcare Products Association applauded the measure. FDA drew attention to concerns about bulk dex abuse through a May 2005 "Talk Paper" (1"The Tan Sheet" May 30, 2005, p. 3)...

You may also be interested in...

CHPA Pushes Federal Legislation, PSAs To Curb Dextromethorphan Abuse

The Consumer Healthcare Products Association is actively working to encourage introduction of companion legislation in the Senate for a bill that would restrict the sale and distribution of bulk forms of dextromethorphan

FDA Dextromethorphan Advisory Marks Growing Concern Over Abuse

An FDA "Talk Paper" is raising the profile of dextromethorphan (DXM) abuse issues from a peripheral concern to a visible public health problem

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts